Taking pre-exposure prophylaxis (PrEP) "on demand," meaning only around the time of sexual intercourse was effective in preventing HIV infection among men who have sex with men (MSM), Jean-Michel Molina, M.D., of the University of Paris Diderot repor...
The first large-scale human studies for the development of an anti-HIV vaccine using monoclonal antibodies have just begun enrollment. These are passive immunizations using a laboratory-generated antibody that proved to be highly effective in animal ...
Final results of HPTN 052, the watershed randomized trial that positioned antiretroviral therapy (ART) as an HIV prevention strategy, indicate that participants starting ART at a high CD4 count sustained a 93% lower risk of transmitting HIV to sex pa...
Consistent Use of Dapivirine Vaginal Ring Could Offer More Than 75% HIV Protection, New Data Suggests
Seventy-five percent: That's how much HIV protection women might be able to expect from a flexible silicone ring loaded with the antiretroviral medicine dapivirine when they put it in their vaginas and leave it there.
Rilpivirine (Edurant) remained detectable in plasma and female genital tract fluids for 18 months or more after a single injection of a long-acting non-nucleoside for HIV pre-exposure prophylaxis (PrEP).
Twice-daily oral maraviroc (Selzentry, Celsentri) failed to prevent SIV infection in infant macaques orally exposed to the virus, but the findings do not rule out potential use in human infants.
No woman taking daily maraviroc pre-exposure prophylaxis (PrEP) with or without tenofovir (TDF, Viread) or emtricitabine (FTC, Emtriva) became infected with HIV through 48 weeks in a randomized, double-blind, 188-woman U.S. study.
Fred Schaich spoke with Paul Stoffels at this year's International AIDS Conference about his career in HIV drug development and a current trial of three prime-boost HIV vaccines.
On behalf of IFARA, Fred Schaich spoke with Glenda Gray about country-specific HIV vaccine research presented at this year's International AIDS Conference and the real-world problems that must be overcome.
On behalf of IFARA, Fred Schaich spoke with Carl Dieffenbach about HIV prevention research presented at this year's International AIDS Conference and what the next prevention revolution is likely to be.